nodes	percent_of_prediction	percent_of_DWPC	metapath
Pancuronium—SLC22A1—prostate cancer	0.628	1	CbGaD
Pancuronium—SLC22A2—Estradiol—prostate cancer	0.054	0.535	CbGbCtD
Pancuronium—SLC22A1—Estradiol—prostate cancer	0.0469	0.465	CbGbCtD
Pancuronium—CHRM3—ureter—prostate cancer	0.0188	0.342	CbGeAlD
Pancuronium—Pre-existing disease—Estradiol—prostate cancer	0.0164	0.167	CcSEcCtD
Pancuronium—CHRNA1—prostate gland—prostate cancer	0.00545	0.0991	CbGeAlD
Pancuronium—CHRNA2—prostate gland—prostate cancer	0.00453	0.0822	CbGeAlD
Pancuronium—CHRNB1—prostate gland—prostate cancer	0.00421	0.0765	CbGeAlD
Pancuronium—CHRM2—prostate gland—prostate cancer	0.0027	0.049	CbGeAlD
Pancuronium—Vecuronium—SLC22A1—prostate cancer	0.00256	0.529	CrCbGaD
Pancuronium—SLC22A2—renal system—prostate cancer	0.00256	0.0465	CbGeAlD
Pancuronium—Rocuronium—SLC22A1—prostate cancer	0.00228	0.471	CrCbGaD
Pancuronium—CHRM3—prostate gland—prostate cancer	0.0022	0.0399	CbGeAlD
Pancuronium—Redness—Estradiol—prostate cancer	0.00202	0.0207	CcSEcCtD
Pancuronium—Muscular weakness—Degarelix—prostate cancer	0.00196	0.02	CcSEcCtD
Pancuronium—CHRNB1—testis—prostate cancer	0.00186	0.0337	CbGeAlD
Pancuronium—SLC22A1—renal system—prostate cancer	0.00181	0.0328	CbGeAlD
Pancuronium—Flushing—Estramustine—prostate cancer	0.0018	0.0184	CcSEcCtD
Pancuronium—BCHE—prostate gland—prostate cancer	0.00179	0.0326	CbGeAlD
Pancuronium—Muscular weakness—Bicalutamide—prostate cancer	0.00158	0.0162	CcSEcCtD
Pancuronium—BCHE—seminal vesicle—prostate cancer	0.00152	0.0276	CbGeAlD
Pancuronium—CHRM3—renal system—prostate cancer	0.0015	0.0272	CbGeAlD
Pancuronium—Erythema—Flutamide—prostate cancer	0.00149	0.0152	CcSEcCtD
Pancuronium—CHRM3—urethra—prostate cancer	0.00147	0.0267	CbGeAlD
Pancuronium—Drug interaction—Estradiol—prostate cancer	0.00147	0.015	CcSEcCtD
Pancuronium—Flushing—Cabazitaxel—prostate cancer	0.00135	0.0137	CcSEcCtD
Pancuronium—CHRNB1—lymph node—prostate cancer	0.00134	0.0244	CbGeAlD
Pancuronium—Erythema—Degarelix—prostate cancer	0.00134	0.0137	CcSEcCtD
Pancuronium—Anaphylactic shock—Estrone—prostate cancer	0.00132	0.0135	CcSEcCtD
Pancuronium—Redness—Docetaxel—prostate cancer	0.0013	0.0133	CcSEcCtD
Pancuronium—Anaphylactoid reaction—Conjugated Estrogens—prostate cancer	0.00128	0.0131	CcSEcCtD
Pancuronium—Erythema—Cabazitaxel—prostate cancer	0.00126	0.0129	CcSEcCtD
Pancuronium—Apnoea—Etoposide—prostate cancer	0.00125	0.0128	CcSEcCtD
Pancuronium—Anaphylactic shock—Estradiol valerate/Dienogest—prostate cancer	0.00115	0.0117	CcSEcCtD
Pancuronium—Anaphylactic shock—Degarelix—prostate cancer	0.00109	0.0112	CcSEcCtD
Pancuronium—Bronchospasm—Conjugated Estrogens—prostate cancer	0.00105	0.0108	CcSEcCtD
Pancuronium—Anaphylactoid reaction—Estradiol—prostate cancer	0.00102	0.0105	CcSEcCtD
Pancuronium—Hypotension—Degarelix—prostate cancer	0.00102	0.0104	CcSEcCtD
Pancuronium—Tachycardia—Cabazitaxel—prostate cancer	0.001	0.0103	CcSEcCtD
Pancuronium—CHRM3—testis—prostate cancer	0.000969	0.0176	CbGeAlD
Pancuronium—Hypotension—Cabazitaxel—prostate cancer	0.000962	0.00983	CcSEcCtD
Pancuronium—Anaphylactoid reaction—Mitoxantrone—prostate cancer	0.000954	0.00975	CcSEcCtD
Pancuronium—Drug interaction—Docetaxel—prostate cancer	0.000948	0.00969	CcSEcCtD
Pancuronium—BCHE—bone marrow—prostate cancer	0.000925	0.0168	CbGeAlD
Pancuronium—Respiratory failure—Docetaxel—prostate cancer	0.000895	0.00915	CcSEcCtD
Pancuronium—Redness—Epirubicin—prostate cancer	0.000879	0.00898	CcSEcCtD
Pancuronium—Rash—Estramustine—prostate cancer	0.000869	0.00888	CcSEcCtD
Pancuronium—Dermatitis—Estramustine—prostate cancer	0.000869	0.00888	CcSEcCtD
Pancuronium—Paralysis—Epirubicin—prostate cancer	0.000854	0.00872	CcSEcCtD
Pancuronium—Hypersensitivity—Estradiol valerate/Dienogest—prostate cancer	0.000847	0.00865	CcSEcCtD
Pancuronium—Rash—Abiraterone—prostate cancer	0.000844	0.00863	CcSEcCtD
Pancuronium—Dermatitis—Abiraterone—prostate cancer	0.000844	0.00862	CcSEcCtD
Pancuronium—Bronchospasm—Estradiol—prostate cancer	0.000843	0.00861	CcSEcCtD
Pancuronium—Rash—Estrone—prostate cancer	0.000831	0.00849	CcSEcCtD
Pancuronium—Dermatitis—Estrone—prostate cancer	0.00083	0.00848	CcSEcCtD
Pancuronium—Redness—Doxorubicin—prostate cancer	0.000813	0.00831	CcSEcCtD
Pancuronium—Hypersensitivity—Degarelix—prostate cancer	0.000805	0.00823	CcSEcCtD
Pancuronium—Anaphylactoid reaction—Etoposide—prostate cancer	0.000794	0.00811	CcSEcCtD
Pancuronium—BCHE—testis—prostate cancer	0.00079	0.0144	CbGeAlD
Pancuronium—Paralysis—Doxorubicin—prostate cancer	0.00079	0.00807	CcSEcCtD
Pancuronium—Rash—Nilutamide—prostate cancer	0.000771	0.00788	CcSEcCtD
Pancuronium—Dermatitis—Nilutamide—prostate cancer	0.000771	0.00788	CcSEcCtD
Pancuronium—Rash—Flutamide—prostate cancer	0.000768	0.00785	CcSEcCtD
Pancuronium—Dermatitis—Flutamide—prostate cancer	0.000767	0.00784	CcSEcCtD
Pancuronium—Hypersensitivity—Cabazitaxel—prostate cancer	0.000759	0.00775	CcSEcCtD
Pancuronium—Erythema—Goserelin—prostate cancer	0.000753	0.00769	CcSEcCtD
Pancuronium—Erythema—Conjugated Estrogens—prostate cancer	0.000746	0.00762	CcSEcCtD
Pancuronium—Rash—Estradiol valerate/Dienogest—prostate cancer	0.000725	0.00741	CcSEcCtD
Pancuronium—Dermatitis—Estradiol valerate/Dienogest—prostate cancer	0.000724	0.0074	CcSEcCtD
Pancuronium—Rash—Degarelix—prostate cancer	0.000689	0.00704	CcSEcCtD
Pancuronium—Dermatitis—Degarelix—prostate cancer	0.000689	0.00704	CcSEcCtD
Pancuronium—Bronchospasm—Etoposide—prostate cancer	0.000653	0.00667	CcSEcCtD
Pancuronium—Hypersensitivity—Bicalutamide—prostate cancer	0.000651	0.00665	CcSEcCtD
Pancuronium—Flushing—Estradiol—prostate cancer	0.000636	0.0065	CcSEcCtD
Pancuronium—Anaphylactic shock—Goserelin—prostate cancer	0.000614	0.00628	CcSEcCtD
Pancuronium—Anaphylactic shock—Conjugated Estrogens—prostate cancer	0.000609	0.00622	CcSEcCtD
Pancuronium—Tachycardia—Goserelin—prostate cancer	0.0006	0.00613	CcSEcCtD
Pancuronium—Erythema—Estradiol—prostate cancer	0.000597	0.0061	CcSEcCtD
Pancuronium—Tachycardia—Conjugated Estrogens—prostate cancer	0.000594	0.00607	CcSEcCtD
Pancuronium—Salivary hypersecretion—Epirubicin—prostate cancer	0.000576	0.00589	CcSEcCtD
Pancuronium—Hypotension—Goserelin—prostate cancer	0.000574	0.00587	CcSEcCtD
Pancuronium—BCHE—lymph node—prostate cancer	0.000573	0.0104	CbGeAlD
Pancuronium—Hypotension—Conjugated Estrogens—prostate cancer	0.000569	0.00581	CcSEcCtD
Pancuronium—Rash—Bicalutamide—prostate cancer	0.000557	0.00569	CcSEcCtD
Pancuronium—Dermatitis—Bicalutamide—prostate cancer	0.000556	0.00569	CcSEcCtD
Pancuronium—Erythema—Mitoxantrone—prostate cancer	0.000556	0.00568	CcSEcCtD
Pancuronium—Hypersensitivity—Ethinyl Estradiol—prostate cancer	0.00055	0.00562	CcSEcCtD
Pancuronium—Muscular weakness—Capecitabine—prostate cancer	0.000545	0.00557	CcSEcCtD
Pancuronium—Bronchospasm—Docetaxel—prostate cancer	0.000543	0.00554	CcSEcCtD
Pancuronium—Salivary hypersecretion—Doxorubicin—prostate cancer	0.000533	0.00545	CcSEcCtD
Pancuronium—Bronchospasm—Capecitabine—prostate cancer	0.000525	0.00537	CcSEcCtD
Pancuronium—Flushing—Etoposide—prostate cancer	0.000493	0.00504	CcSEcCtD
Pancuronium—Anaphylactic shock—Estradiol—prostate cancer	0.000487	0.00498	CcSEcCtD
Pancuronium—Muscular weakness—Prednisone—prostate cancer	0.000486	0.00496	CcSEcCtD
Pancuronium—Tachycardia—Estradiol—prostate cancer	0.000475	0.00486	CcSEcCtD
Pancuronium—Rash—Ethinyl Estradiol—prostate cancer	0.000471	0.00481	CcSEcCtD
Pancuronium—Dermatitis—Ethinyl Estradiol—prostate cancer	0.00047	0.00481	CcSEcCtD
Pancuronium—Anaphylactic shock—Mitoxantrone—prostate cancer	0.000454	0.00464	CcSEcCtD
Pancuronium—Hypersensitivity—Goserelin—prostate cancer	0.000453	0.00463	CcSEcCtD
Pancuronium—Hypersensitivity—Conjugated Estrogens—prostate cancer	0.000448	0.00458	CcSEcCtD
Pancuronium—Anaphylactoid reaction—Epirubicin—prostate cancer	0.000445	0.00455	CcSEcCtD
Pancuronium—Tachycardia—Mitoxantrone—prostate cancer	0.000443	0.00453	CcSEcCtD
Pancuronium—Hypotension—Mitoxantrone—prostate cancer	0.000424	0.00433	CcSEcCtD
Pancuronium—Anaphylactoid reaction—Doxorubicin—prostate cancer	0.000412	0.00421	CcSEcCtD
Pancuronium—Flushing—Docetaxel—prostate cancer	0.00041	0.00419	CcSEcCtD
Pancuronium—Flushing—Capecitabine—prostate cancer	0.000397	0.00405	CcSEcCtD
Pancuronium—Rash—Goserelin—prostate cancer	0.000387	0.00396	CcSEcCtD
Pancuronium—Dermatitis—Goserelin—prostate cancer	0.000387	0.00395	CcSEcCtD
Pancuronium—Erythema—Docetaxel—prostate cancer	0.000384	0.00393	CcSEcCtD
Pancuronium—Rash—Conjugated Estrogens—prostate cancer	0.000384	0.00392	CcSEcCtD
Pancuronium—Dermatitis—Conjugated Estrogens—prostate cancer	0.000383	0.00392	CcSEcCtD
Pancuronium—Muscular weakness—Epirubicin—prostate cancer	0.00038	0.00388	CcSEcCtD
Pancuronium—Anaphylactic shock—Etoposide—prostate cancer	0.000378	0.00386	CcSEcCtD
Pancuronium—Erythema—Capecitabine—prostate cancer	0.000372	0.0038	CcSEcCtD
Pancuronium—Tachycardia—Etoposide—prostate cancer	0.000368	0.00376	CcSEcCtD
Pancuronium—Hypersensitivity—Estradiol—prostate cancer	0.000359	0.00367	CcSEcCtD
Pancuronium—Flushing—Prednisone—prostate cancer	0.000353	0.00361	CcSEcCtD
Pancuronium—Hypotension—Etoposide—prostate cancer	0.000353	0.0036	CcSEcCtD
Pancuronium—Muscular weakness—Doxorubicin—prostate cancer	0.000351	0.00359	CcSEcCtD
Pancuronium—Hypersensitivity—Mitoxantrone—prostate cancer	0.000334	0.00342	CcSEcCtD
Pancuronium—Erythema—Prednisone—prostate cancer	0.000332	0.00339	CcSEcCtD
Pancuronium—Anaphylactic shock—Docetaxel—prostate cancer	0.000314	0.00321	CcSEcCtD
Pancuronium—Rash—Estradiol—prostate cancer	0.000307	0.00314	CcSEcCtD
Pancuronium—Dermatitis—Estradiol—prostate cancer	0.000307	0.00314	CcSEcCtD
Pancuronium—Tachycardia—Docetaxel—prostate cancer	0.000306	0.00313	CcSEcCtD
Pancuronium—Tachycardia—Capecitabine—prostate cancer	0.000296	0.00303	CcSEcCtD
Pancuronium—Hypotension—Docetaxel—prostate cancer	0.000293	0.003	CcSEcCtD
Pancuronium—Rash—Mitoxantrone—prostate cancer	0.000286	0.00292	CcSEcCtD
Pancuronium—Dermatitis—Mitoxantrone—prostate cancer	0.000286	0.00292	CcSEcCtD
Pancuronium—Hypotension—Capecitabine—prostate cancer	0.000284	0.0029	CcSEcCtD
Pancuronium—Hypersensitivity—Etoposide—prostate cancer	0.000278	0.00284	CcSEcCtD
Pancuronium—Flushing—Epirubicin—prostate cancer	0.000276	0.00282	CcSEcCtD
Pancuronium—Anaphylactic shock—Prednisone—prostate cancer	0.000271	0.00276	CcSEcCtD
Pancuronium—Tachycardia—Prednisone—prostate cancer	0.000264	0.0027	CcSEcCtD
Pancuronium—Erythema—Epirubicin—prostate cancer	0.000259	0.00265	CcSEcCtD
Pancuronium—Flushing—Doxorubicin—prostate cancer	0.000256	0.00261	CcSEcCtD
Pancuronium—Erythema—Doxorubicin—prostate cancer	0.00024	0.00245	CcSEcCtD
Pancuronium—Rash—Etoposide—prostate cancer	0.000238	0.00243	CcSEcCtD
Pancuronium—Dermatitis—Etoposide—prostate cancer	0.000238	0.00243	CcSEcCtD
Pancuronium—Hypersensitivity—Docetaxel—prostate cancer	0.000231	0.00236	CcSEcCtD
Pancuronium—Hypersensitivity—Capecitabine—prostate cancer	0.000224	0.00229	CcSEcCtD
Pancuronium—Anaphylactic shock—Epirubicin—prostate cancer	0.000212	0.00216	CcSEcCtD
Pancuronium—Tachycardia—Epirubicin—prostate cancer	0.000207	0.00211	CcSEcCtD
Pancuronium—Hypersensitivity—Prednisone—prostate cancer	0.000199	0.00204	CcSEcCtD
Pancuronium—Rash—Docetaxel—prostate cancer	0.000198	0.00202	CcSEcCtD
Pancuronium—Hypotension—Epirubicin—prostate cancer	0.000198	0.00202	CcSEcCtD
Pancuronium—Dermatitis—Docetaxel—prostate cancer	0.000198	0.00202	CcSEcCtD
Pancuronium—Anaphylactic shock—Doxorubicin—prostate cancer	0.000196	0.002	CcSEcCtD
Pancuronium—Rash—Capecitabine—prostate cancer	0.000192	0.00196	CcSEcCtD
Pancuronium—Dermatitis—Capecitabine—prostate cancer	0.000191	0.00196	CcSEcCtD
Pancuronium—Tachycardia—Doxorubicin—prostate cancer	0.000191	0.00195	CcSEcCtD
Pancuronium—Hypotension—Doxorubicin—prostate cancer	0.000183	0.00187	CcSEcCtD
Pancuronium—Rash—Prednisone—prostate cancer	0.000171	0.00174	CcSEcCtD
Pancuronium—Dermatitis—Prednisone—prostate cancer	0.00017	0.00174	CcSEcCtD
Pancuronium—Hypersensitivity—Epirubicin—prostate cancer	0.000156	0.00159	CcSEcCtD
Pancuronium—Hypersensitivity—Doxorubicin—prostate cancer	0.000144	0.00147	CcSEcCtD
Pancuronium—Rash—Epirubicin—prostate cancer	0.000133	0.00136	CcSEcCtD
Pancuronium—Dermatitis—Epirubicin—prostate cancer	0.000133	0.00136	CcSEcCtD
Pancuronium—Rash—Doxorubicin—prostate cancer	0.000123	0.00126	CcSEcCtD
Pancuronium—Dermatitis—Doxorubicin—prostate cancer	0.000123	0.00126	CcSEcCtD
Pancuronium—CHRM3—Signaling Pathways—PRKCZ—prostate cancer	1.29e-05	0.000114	CbGpPWpGaD
Pancuronium—SLC22A1—Metabolism—COMT—prostate cancer	1.29e-05	0.000114	CbGpPWpGaD
Pancuronium—SLC22A1—Metabolism—GSTP1—prostate cancer	1.28e-05	0.000113	CbGpPWpGaD
Pancuronium—CHRM3—Metabolism—CYP19A1—prostate cancer	1.28e-05	0.000113	CbGpPWpGaD
Pancuronium—SLC22A2—Metabolism—TYMS—prostate cancer	1.28e-05	0.000113	CbGpPWpGaD
Pancuronium—CHRM2—Signaling Pathways—PRKCZ—prostate cancer	1.28e-05	0.000113	CbGpPWpGaD
Pancuronium—SLC22A2—Metabolism—GSTM1—prostate cancer	1.27e-05	0.000112	CbGpPWpGaD
Pancuronium—SLC22A1—Metabolism—ITPR1—prostate cancer	1.26e-05	0.000112	CbGpPWpGaD
Pancuronium—CHRM3—GPCR downstream signaling—PIK3CG—prostate cancer	1.26e-05	0.000111	CbGpPWpGaD
Pancuronium—BCHE—Metabolism—MTHFR—prostate cancer	1.25e-05	0.000111	CbGpPWpGaD
Pancuronium—CHRM2—GPCR downstream signaling—PIK3CG—prostate cancer	1.25e-05	0.00011	CbGpPWpGaD
Pancuronium—CHRM3—Signaling Pathways—PARP1—prostate cancer	1.25e-05	0.00011	CbGpPWpGaD
Pancuronium—CHRM3—Signaling Pathways—FGFR4—prostate cancer	1.25e-05	0.00011	CbGpPWpGaD
Pancuronium—SLC22A2—Metabolism—LPL—prostate cancer	1.24e-05	0.00011	CbGpPWpGaD
Pancuronium—CHRM3—Metabolism—RXRA—prostate cancer	1.24e-05	0.000109	CbGpPWpGaD
Pancuronium—CHRM2—Signaling Pathways—PARP1—prostate cancer	1.23e-05	0.000109	CbGpPWpGaD
Pancuronium—CHRM2—Signaling Pathways—FGFR4—prostate cancer	1.23e-05	0.000109	CbGpPWpGaD
Pancuronium—CHRM3—Signaling Pathways—CALCA—prostate cancer	1.23e-05	0.000109	CbGpPWpGaD
Pancuronium—BCHE—Metabolism—PPARA—prostate cancer	1.23e-05	0.000109	CbGpPWpGaD
Pancuronium—CHRM2—Signaling Pathways—CALCA—prostate cancer	1.22e-05	0.000108	CbGpPWpGaD
Pancuronium—CHRM3—Signaling Pathways—CXCL12—prostate cancer	1.2e-05	0.000106	CbGpPWpGaD
Pancuronium—SLC22A2—Metabolism—CYP1A1—prostate cancer	1.2e-05	0.000106	CbGpPWpGaD
Pancuronium—SLC22A1—Metabolism—TYMS—prostate cancer	1.19e-05	0.000105	CbGpPWpGaD
Pancuronium—CHRM3—Metabolism—COMT—prostate cancer	1.19e-05	0.000105	CbGpPWpGaD
Pancuronium—CHRM2—Signaling Pathways—CXCL12—prostate cancer	1.19e-05	0.000105	CbGpPWpGaD
Pancuronium—SLC22A2—Metabolism—ERCC2—prostate cancer	1.19e-05	0.000105	CbGpPWpGaD
Pancuronium—CHRM3—Metabolism—GSTP1—prostate cancer	1.19e-05	0.000105	CbGpPWpGaD
Pancuronium—SLC22A1—Metabolism—GSTM1—prostate cancer	1.18e-05	0.000104	CbGpPWpGaD
Pancuronium—CHRM3—Metabolism—ITPR1—prostate cancer	1.17e-05	0.000103	CbGpPWpGaD
Pancuronium—SLC22A1—Metabolism—LPL—prostate cancer	1.16e-05	0.000102	CbGpPWpGaD
Pancuronium—BCHE—Metabolism—CAV1—prostate cancer	1.16e-05	0.000102	CbGpPWpGaD
Pancuronium—CHRM3—Signaling by GPCR—PIK3CG—prostate cancer	1.15e-05	0.000101	CbGpPWpGaD
Pancuronium—CHRM2—Signaling by GPCR—PIK3CG—prostate cancer	1.13e-05	0.0001	CbGpPWpGaD
Pancuronium—CHRM3—Signaling Pathways—CASP9—prostate cancer	1.13e-05	0.0001	CbGpPWpGaD
Pancuronium—CHRM2—Signaling Pathways—CASP9—prostate cancer	1.12e-05	9.91e-05	CbGpPWpGaD
Pancuronium—SLC22A2—Metabolism—MTHFR—prostate cancer	1.12e-05	9.89e-05	CbGpPWpGaD
Pancuronium—SLC22A1—Metabolism—CYP1A1—prostate cancer	1.12e-05	9.88e-05	CbGpPWpGaD
Pancuronium—SLC22A1—Metabolism—ERCC2—prostate cancer	1.11e-05	9.8e-05	CbGpPWpGaD
Pancuronium—CHRM3—GPCR downstream signaling—PIK3CD—prostate cancer	1.11e-05	9.8e-05	CbGpPWpGaD
Pancuronium—BCHE—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	1.1e-05	9.75e-05	CbGpPWpGaD
Pancuronium—CHRM3—Metabolism—TYMS—prostate cancer	1.1e-05	9.74e-05	CbGpPWpGaD
Pancuronium—CHRM2—GPCR downstream signaling—PIK3CD—prostate cancer	1.1e-05	9.7e-05	CbGpPWpGaD
Pancuronium—SLC22A2—Metabolism—PPARA—prostate cancer	1.1e-05	9.7e-05	CbGpPWpGaD
Pancuronium—CHRM3—Signaling Pathways—PRKCQ—prostate cancer	1.1e-05	9.7e-05	CbGpPWpGaD
Pancuronium—CHRM3—Signaling Pathways—NGFR—prostate cancer	1.1e-05	9.7e-05	CbGpPWpGaD
Pancuronium—CHRM3—Metabolism—GSTM1—prostate cancer	1.09e-05	9.63e-05	CbGpPWpGaD
Pancuronium—CHRM2—Signaling Pathways—PRKCQ—prostate cancer	1.09e-05	9.6e-05	CbGpPWpGaD
Pancuronium—CHRM2—Signaling Pathways—NGFR—prostate cancer	1.09e-05	9.6e-05	CbGpPWpGaD
Pancuronium—CHRM3—Signaling Pathways—MAP3K7—prostate cancer	1.08e-05	9.58e-05	CbGpPWpGaD
Pancuronium—CHRM2—Signaling Pathways—MAP3K7—prostate cancer	1.07e-05	9.49e-05	CbGpPWpGaD
Pancuronium—CHRM3—Metabolism—LPL—prostate cancer	1.07e-05	9.45e-05	CbGpPWpGaD
Pancuronium—BCHE—Metabolism—PIK3CG—prostate cancer	1.05e-05	9.3e-05	CbGpPWpGaD
Pancuronium—SLC22A1—Metabolism—MTHFR—prostate cancer	1.04e-05	9.21e-05	CbGpPWpGaD
Pancuronium—CHRM3—Signaling Pathways—FGF10—prostate cancer	1.04e-05	9.21e-05	CbGpPWpGaD
Pancuronium—CHRM3—Metabolism—CYP1A1—prostate cancer	1.03e-05	9.13e-05	CbGpPWpGaD
Pancuronium—CHRM2—Signaling Pathways—FGF10—prostate cancer	1.03e-05	9.12e-05	CbGpPWpGaD
Pancuronium—SLC22A2—Metabolism—CAV1—prostate cancer	1.03e-05	9.12e-05	CbGpPWpGaD
Pancuronium—CHRM3—Signaling Pathways—ADRB2—prostate cancer	1.03e-05	9.12e-05	CbGpPWpGaD
Pancuronium—CHRM3—Metabolism—ERCC2—prostate cancer	1.02e-05	9.06e-05	CbGpPWpGaD
Pancuronium—SLC22A1—Metabolism—PPARA—prostate cancer	1.02e-05	9.04e-05	CbGpPWpGaD
Pancuronium—CHRM2—Signaling Pathways—ADRB2—prostate cancer	1.02e-05	9.03e-05	CbGpPWpGaD
Pancuronium—CHRM3—GPCR downstream signaling—JAK2—prostate cancer	1.02e-05	8.99e-05	CbGpPWpGaD
Pancuronium—CHRM3—Signaling by GPCR—MAP2K1—prostate cancer	1.01e-05	8.96e-05	CbGpPWpGaD
Pancuronium—CHRM2—GPCR downstream signaling—JAK2—prostate cancer	1.01e-05	8.91e-05	CbGpPWpGaD
Pancuronium—CHRM3—Signaling by GPCR—PIK3CD—prostate cancer	1.01e-05	8.9e-05	CbGpPWpGaD
Pancuronium—CHRM3—Signaling Pathways—VAV3—prostate cancer	1.01e-05	8.89e-05	CbGpPWpGaD
Pancuronium—CHRM2—Signaling by GPCR—MAP2K1—prostate cancer	1e-05	8.87e-05	CbGpPWpGaD
Pancuronium—CHRM2—Signaling by GPCR—PIK3CD—prostate cancer	9.97e-06	8.81e-05	CbGpPWpGaD
Pancuronium—CHRM2—Signaling Pathways—VAV3—prostate cancer	9.96e-06	8.8e-05	CbGpPWpGaD
Pancuronium—BCHE—Metabolism—INS—prostate cancer	9.96e-06	8.8e-05	CbGpPWpGaD
Pancuronium—CHRM3—Signaling Pathways—TGFBR2—prostate cancer	9.92e-06	8.76e-05	CbGpPWpGaD
Pancuronium—CHRM2—Signaling Pathways—TGFBR2—prostate cancer	9.82e-06	8.68e-05	CbGpPWpGaD
Pancuronium—CHRM3—Signaling Pathways—ITPR1—prostate cancer	9.76e-06	8.62e-05	CbGpPWpGaD
Pancuronium—BCHE—Metabolism—CREBBP—prostate cancer	9.76e-06	8.62e-05	CbGpPWpGaD
Pancuronium—CHRM3—GPCR downstream signaling—PIK3CB—prostate cancer	9.67e-06	8.54e-05	CbGpPWpGaD
Pancuronium—CHRM2—Signaling Pathways—ITPR1—prostate cancer	9.66e-06	8.54e-05	CbGpPWpGaD
Pancuronium—CHRM3—Metabolism—MTHFR—prostate cancer	9.63e-06	8.51e-05	CbGpPWpGaD
Pancuronium—SLC22A1—Metabolism—CAV1—prostate cancer	9.62e-06	8.5e-05	CbGpPWpGaD
Pancuronium—CHRM2—GPCR downstream signaling—PIK3CB—prostate cancer	9.57e-06	8.46e-05	CbGpPWpGaD
Pancuronium—CHRM3—Metabolism—PPARA—prostate cancer	9.45e-06	8.35e-05	CbGpPWpGaD
Pancuronium—SLC22A2—Metabolism—PIK3CG—prostate cancer	9.4e-06	8.31e-05	CbGpPWpGaD
Pancuronium—CHRM3—Signaling Pathways—IGF1R—prostate cancer	9.33e-06	8.25e-05	CbGpPWpGaD
Pancuronium—CHRM3—GPCR downstream signaling—CXCL8—prostate cancer	9.29e-06	8.21e-05	CbGpPWpGaD
Pancuronium—BCHE—Metabolism—PIK3CD—prostate cancer	9.25e-06	8.18e-05	CbGpPWpGaD
Pancuronium—CHRM3—Signaling by GPCR—JAK2—prostate cancer	9.24e-06	8.17e-05	CbGpPWpGaD
Pancuronium—CHRM2—Signaling Pathways—IGF1R—prostate cancer	9.24e-06	8.17e-05	CbGpPWpGaD
Pancuronium—CHRM2—GPCR downstream signaling—CXCL8—prostate cancer	9.2e-06	8.13e-05	CbGpPWpGaD
Pancuronium—CHRM2—Signaling by GPCR—JAK2—prostate cancer	9.15e-06	8.09e-05	CbGpPWpGaD
Pancuronium—CHRM3—Signaling Pathways—LPL—prostate cancer	8.95e-06	7.91e-05	CbGpPWpGaD
Pancuronium—SLC22A2—Metabolism—INS—prostate cancer	8.9e-06	7.86e-05	CbGpPWpGaD
Pancuronium—CHRM3—Metabolism—CAV1—prostate cancer	8.89e-06	7.85e-05	CbGpPWpGaD
Pancuronium—CHRM3—GPCR downstream signaling—IL2—prostate cancer	8.88e-06	7.84e-05	CbGpPWpGaD
Pancuronium—CHRM3—Signaling Pathways—PDGFRB—prostate cancer	8.87e-06	7.83e-05	CbGpPWpGaD
Pancuronium—CHRM2—Signaling Pathways—LPL—prostate cancer	8.86e-06	7.83e-05	CbGpPWpGaD
Pancuronium—CHRM2—GPCR downstream signaling—IL2—prostate cancer	8.79e-06	7.77e-05	CbGpPWpGaD
Pancuronium—CHRM2—Signaling Pathways—PDGFRB—prostate cancer	8.78e-06	7.76e-05	CbGpPWpGaD
Pancuronium—CHRM3—Signaling by GPCR—PIK3CB—prostate cancer	8.78e-06	7.76e-05	CbGpPWpGaD
Pancuronium—SLC22A1—Metabolism—PIK3CG—prostate cancer	8.76e-06	7.74e-05	CbGpPWpGaD
Pancuronium—BCHE—Metabolism—NOS3—prostate cancer	8.74e-06	7.72e-05	CbGpPWpGaD
Pancuronium—SLC22A2—Metabolism—CREBBP—prostate cancer	8.72e-06	7.7e-05	CbGpPWpGaD
Pancuronium—CHRM2—Signaling by GPCR—PIK3CB—prostate cancer	8.69e-06	7.68e-05	CbGpPWpGaD
Pancuronium—CHRM3—Signaling Pathways—ITGB3—prostate cancer	8.64e-06	7.63e-05	CbGpPWpGaD
Pancuronium—CHRM2—Signaling Pathways—ITGB3—prostate cancer	8.56e-06	7.56e-05	CbGpPWpGaD
Pancuronium—CHRM3—Signaling by GPCR—CXCL8—prostate cancer	8.44e-06	7.45e-05	CbGpPWpGaD
Pancuronium—CHRM3—Signaling Pathways—ERBB3—prostate cancer	8.38e-06	7.41e-05	CbGpPWpGaD
Pancuronium—CHRM3—Signaling Pathways—FGFR2—prostate cancer	8.37e-06	7.39e-05	CbGpPWpGaD
Pancuronium—CHRM2—Signaling by GPCR—CXCL8—prostate cancer	8.35e-06	7.38e-05	CbGpPWpGaD
Pancuronium—CHRM2—Signaling Pathways—ERBB3—prostate cancer	8.3e-06	7.33e-05	CbGpPWpGaD
Pancuronium—SLC22A1—Metabolism—INS—prostate cancer	8.29e-06	7.33e-05	CbGpPWpGaD
Pancuronium—CHRM2—Signaling Pathways—FGFR2—prostate cancer	8.29e-06	7.32e-05	CbGpPWpGaD
Pancuronium—SLC22A2—Metabolism—PIK3CD—prostate cancer	8.26e-06	7.3e-05	CbGpPWpGaD
Pancuronium—SLC22A1—Metabolism—CREBBP—prostate cancer	8.12e-06	7.18e-05	CbGpPWpGaD
Pancuronium—CHRM3—Metabolism—PIK3CG—prostate cancer	8.09e-06	7.15e-05	CbGpPWpGaD
Pancuronium—BCHE—Metabolism—PIK3CB—prostate cancer	8.07e-06	7.13e-05	CbGpPWpGaD
Pancuronium—CHRM3—Signaling by GPCR—IL2—prostate cancer	8.06e-06	7.12e-05	CbGpPWpGaD
Pancuronium—CHRM3—Signaling Pathways—TERT—prostate cancer	8.03e-06	7.1e-05	CbGpPWpGaD
Pancuronium—BCHE—Metabolism—PTGS2—prostate cancer	7.99e-06	7.06e-05	CbGpPWpGaD
Pancuronium—CHRM2—Signaling by GPCR—IL2—prostate cancer	7.98e-06	7.05e-05	CbGpPWpGaD
Pancuronium—CHRM2—Signaling Pathways—TERT—prostate cancer	7.95e-06	7.03e-05	CbGpPWpGaD
Pancuronium—SLC22A2—Metabolism—NOS3—prostate cancer	7.8e-06	6.9e-05	CbGpPWpGaD
Pancuronium—SLC22A1—Metabolism—PIK3CD—prostate cancer	7.7e-06	6.81e-05	CbGpPWpGaD
Pancuronium—CHRM3—Signaling Pathways—HIF1A—prostate cancer	7.68e-06	6.79e-05	CbGpPWpGaD
Pancuronium—CHRM3—Metabolism—INS—prostate cancer	7.66e-06	6.77e-05	CbGpPWpGaD
Pancuronium—CHRM2—Signaling Pathways—HIF1A—prostate cancer	7.61e-06	6.72e-05	CbGpPWpGaD
Pancuronium—CHRM3—Metabolism—CREBBP—prostate cancer	7.5e-06	6.63e-05	CbGpPWpGaD
Pancuronium—CHRM3—Signaling Pathways—LEP—prostate cancer	7.5e-06	6.63e-05	CbGpPWpGaD
Pancuronium—CHRM3—Signaling Pathways—CAV1—prostate cancer	7.43e-06	6.57e-05	CbGpPWpGaD
Pancuronium—CHRM2—Signaling Pathways—LEP—prostate cancer	7.43e-06	6.56e-05	CbGpPWpGaD
Pancuronium—CHRM2—Signaling Pathways—CAV1—prostate cancer	7.36e-06	6.5e-05	CbGpPWpGaD
Pancuronium—CHRM3—Signaling Pathways—KDR—prostate cancer	7.35e-06	6.49e-05	CbGpPWpGaD
Pancuronium—CHRM2—Signaling Pathways—KDR—prostate cancer	7.28e-06	6.43e-05	CbGpPWpGaD
Pancuronium—SLC22A1—Metabolism—NOS3—prostate cancer	7.27e-06	6.43e-05	CbGpPWpGaD
Pancuronium—SLC22A2—Metabolism—PIK3CB—prostate cancer	7.2e-06	6.36e-05	CbGpPWpGaD
Pancuronium—CHRM3—Signaling Pathways—ESR1—prostate cancer	7.16e-06	6.33e-05	CbGpPWpGaD
Pancuronium—SLC22A2—Metabolism—PTGS2—prostate cancer	7.14e-06	6.31e-05	CbGpPWpGaD
Pancuronium—CHRM3—Metabolism—PIK3CD—prostate cancer	7.12e-06	6.29e-05	CbGpPWpGaD
Pancuronium—CHRM2—Signaling Pathways—ESR1—prostate cancer	7.09e-06	6.26e-05	CbGpPWpGaD
Pancuronium—CHRM3—Signaling Pathways—BAD—prostate cancer	6.99e-06	6.17e-05	CbGpPWpGaD
Pancuronium—BCHE—Metabolism—PTEN—prostate cancer	6.97e-06	6.16e-05	CbGpPWpGaD
Pancuronium—CHRM2—Signaling Pathways—BAD—prostate cancer	6.92e-06	6.11e-05	CbGpPWpGaD
Pancuronium—CHRM3—Signaling Pathways—APC—prostate cancer	6.77e-06	5.98e-05	CbGpPWpGaD
Pancuronium—CHRM3—Signaling Pathways—PIK3CG—prostate cancer	6.77e-06	5.98e-05	CbGpPWpGaD
Pancuronium—CHRM3—Metabolism—NOS3—prostate cancer	6.72e-06	5.94e-05	CbGpPWpGaD
Pancuronium—SLC22A1—Metabolism—PIK3CB—prostate cancer	6.71e-06	5.93e-05	CbGpPWpGaD
Pancuronium—CHRM2—Signaling Pathways—PIK3CG—prostate cancer	6.7e-06	5.92e-05	CbGpPWpGaD
Pancuronium—CHRM2—Signaling Pathways—APC—prostate cancer	6.7e-06	5.92e-05	CbGpPWpGaD
Pancuronium—CHRM3—Signaling Pathways—EGF—prostate cancer	6.69e-06	5.91e-05	CbGpPWpGaD
Pancuronium—CHRM3—Signaling Pathways—IRS1—prostate cancer	6.69e-06	5.91e-05	CbGpPWpGaD
Pancuronium—SLC22A1—Metabolism—PTGS2—prostate cancer	6.65e-06	5.88e-05	CbGpPWpGaD
Pancuronium—BCHE—Metabolism—EP300—prostate cancer	6.65e-06	5.87e-05	CbGpPWpGaD
Pancuronium—CHRM2—Signaling Pathways—EGF—prostate cancer	6.62e-06	5.85e-05	CbGpPWpGaD
Pancuronium—CHRM2—Signaling Pathways—IRS1—prostate cancer	6.62e-06	5.85e-05	CbGpPWpGaD
Pancuronium—CHRM3—Signaling Pathways—GSK3B—prostate cancer	6.49e-06	5.74e-05	CbGpPWpGaD
Pancuronium—CHRM2—Signaling Pathways—GSK3B—prostate cancer	6.43e-06	5.68e-05	CbGpPWpGaD
Pancuronium—CHRM3—Signaling Pathways—INS—prostate cancer	6.41e-06	5.66e-05	CbGpPWpGaD
Pancuronium—CHRM2—Signaling Pathways—INS—prostate cancer	6.34e-06	5.61e-05	CbGpPWpGaD
Pancuronium—CHRM3—Signaling Pathways—CREBBP—prostate cancer	6.27e-06	5.54e-05	CbGpPWpGaD
Pancuronium—SLC22A2—Metabolism—PTEN—prostate cancer	6.22e-06	5.5e-05	CbGpPWpGaD
Pancuronium—CHRM2—Signaling Pathways—CREBBP—prostate cancer	6.21e-06	5.49e-05	CbGpPWpGaD
Pancuronium—CHRM3—Metabolism—PIK3CB—prostate cancer	6.2e-06	5.48e-05	CbGpPWpGaD
Pancuronium—CHRM3—Signaling Pathways—IGF1—prostate cancer	6.2e-06	5.48e-05	CbGpPWpGaD
Pancuronium—CHRM3—Signaling by GPCR—EGFR—prostate cancer	6.17e-06	5.45e-05	CbGpPWpGaD
Pancuronium—CHRM3—Metabolism—PTGS2—prostate cancer	6.14e-06	5.43e-05	CbGpPWpGaD
Pancuronium—CHRM2—Signaling Pathways—IGF1—prostate cancer	6.14e-06	5.42e-05	CbGpPWpGaD
Pancuronium—CHRM2—Signaling by GPCR—EGFR—prostate cancer	6.11e-06	5.4e-05	CbGpPWpGaD
Pancuronium—CHRM3—Signaling Pathways—MAP2K1—prostate cancer	5.99e-06	5.29e-05	CbGpPWpGaD
Pancuronium—CHRM3—Signaling Pathways—PIK3CD—prostate cancer	5.95e-06	5.26e-05	CbGpPWpGaD
Pancuronium—SLC22A2—Metabolism—EP300—prostate cancer	5.94e-06	5.25e-05	CbGpPWpGaD
Pancuronium—CHRM2—Signaling Pathways—MAP2K1—prostate cancer	5.93e-06	5.24e-05	CbGpPWpGaD
Pancuronium—CHRM3—GPCR downstream signaling—PIK3CA—prostate cancer	5.89e-06	5.21e-05	CbGpPWpGaD
Pancuronium—CHRM2—Signaling Pathways—PIK3CD—prostate cancer	5.89e-06	5.21e-05	CbGpPWpGaD
Pancuronium—CHRM3—Signaling Pathways—SERPINE1—prostate cancer	5.88e-06	5.2e-05	CbGpPWpGaD
Pancuronium—CHRM2—GPCR downstream signaling—PIK3CA—prostate cancer	5.84e-06	5.16e-05	CbGpPWpGaD
Pancuronium—CHRM2—Signaling Pathways—SERPINE1—prostate cancer	5.83e-06	5.15e-05	CbGpPWpGaD
Pancuronium—CHRM3—Signaling by GPCR—KRAS—prostate cancer	5.82e-06	5.15e-05	CbGpPWpGaD
Pancuronium—SLC22A1—Metabolism—PTEN—prostate cancer	5.8e-06	5.13e-05	CbGpPWpGaD
Pancuronium—CHRM2—Signaling by GPCR—KRAS—prostate cancer	5.77e-06	5.1e-05	CbGpPWpGaD
Pancuronium—CHRM3—Signaling Pathways—FGF2—prostate cancer	5.7e-06	5.03e-05	CbGpPWpGaD
Pancuronium—CHRM2—Signaling Pathways—FGF2—prostate cancer	5.64e-06	4.98e-05	CbGpPWpGaD
Pancuronium—CHRM3—Signaling Pathways—NOS3—prostate cancer	5.62e-06	4.96e-05	CbGpPWpGaD
Pancuronium—CHRM2—Signaling Pathways—NOS3—prostate cancer	5.56e-06	4.92e-05	CbGpPWpGaD
Pancuronium—SLC22A1—Metabolism—EP300—prostate cancer	5.53e-06	4.89e-05	CbGpPWpGaD
Pancuronium—CHRM3—Signaling Pathways—JAK2—prostate cancer	5.46e-06	4.82e-05	CbGpPWpGaD
Pancuronium—CHRM2—Signaling Pathways—JAK2—prostate cancer	5.41e-06	4.78e-05	CbGpPWpGaD
Pancuronium—CHRM3—Metabolism—PTEN—prostate cancer	5.36e-06	4.74e-05	CbGpPWpGaD
Pancuronium—CHRM3—Signaling by GPCR—PIK3CA—prostate cancer	5.35e-06	4.73e-05	CbGpPWpGaD
Pancuronium—CHRM3—Signaling Pathways—MDM2—prostate cancer	5.33e-06	4.71e-05	CbGpPWpGaD
Pancuronium—CHRM2—Signaling by GPCR—PIK3CA—prostate cancer	5.3e-06	4.68e-05	CbGpPWpGaD
Pancuronium—CHRM2—Signaling Pathways—MDM2—prostate cancer	5.28e-06	4.66e-05	CbGpPWpGaD
Pancuronium—CHRM3—Signaling Pathways—ERBB2—prostate cancer	5.25e-06	4.64e-05	CbGpPWpGaD
Pancuronium—CHRM2—Signaling Pathways—ERBB2—prostate cancer	5.2e-06	4.6e-05	CbGpPWpGaD
Pancuronium—CHRM3—Signaling Pathways—PIK3CB—prostate cancer	5.19e-06	4.58e-05	CbGpPWpGaD
Pancuronium—CHRM2—Signaling Pathways—PIK3CB—prostate cancer	5.14e-06	4.54e-05	CbGpPWpGaD
Pancuronium—CHRM3—Metabolism—EP300—prostate cancer	5.11e-06	4.52e-05	CbGpPWpGaD
Pancuronium—CHRM3—Signaling Pathways—CXCL8—prostate cancer	4.98e-06	4.4e-05	CbGpPWpGaD
Pancuronium—CHRM2—Signaling Pathways—CXCL8—prostate cancer	4.93e-06	4.36e-05	CbGpPWpGaD
Pancuronium—BCHE—Metabolism—PIK3CA—prostate cancer	4.92e-06	4.34e-05	CbGpPWpGaD
Pancuronium—CHRM3—Signaling Pathways—CDKN1B—prostate cancer	4.87e-06	4.3e-05	CbGpPWpGaD
Pancuronium—CHRM2—Signaling Pathways—CDKN1B—prostate cancer	4.82e-06	4.26e-05	CbGpPWpGaD
Pancuronium—CHRM3—GPCR downstream signaling—AKT1—prostate cancer	4.81e-06	4.25e-05	CbGpPWpGaD
Pancuronium—CHRM3—Signaling Pathways—CASP3—prostate cancer	4.77e-06	4.21e-05	CbGpPWpGaD
Pancuronium—CHRM2—GPCR downstream signaling—AKT1—prostate cancer	4.77e-06	4.21e-05	CbGpPWpGaD
Pancuronium—CHRM3—Signaling Pathways—IL2—prostate cancer	4.76e-06	4.21e-05	CbGpPWpGaD
Pancuronium—CHRM3—Signaling by GPCR—IL6—prostate cancer	4.74e-06	4.19e-05	CbGpPWpGaD
Pancuronium—CHRM2—Signaling Pathways—CASP3—prostate cancer	4.72e-06	4.17e-05	CbGpPWpGaD
Pancuronium—CHRM2—Signaling Pathways—IL2—prostate cancer	4.72e-06	4.17e-05	CbGpPWpGaD
Pancuronium—CHRM2—Signaling by GPCR—IL6—prostate cancer	4.69e-06	4.15e-05	CbGpPWpGaD
Pancuronium—CHRM3—Signaling Pathways—CCND1—prostate cancer	4.64e-06	4.1e-05	CbGpPWpGaD
Pancuronium—CHRM2—Signaling Pathways—CCND1—prostate cancer	4.6e-06	4.06e-05	CbGpPWpGaD
Pancuronium—CHRM3—Signaling Pathways—CTNNB1—prostate cancer	4.6e-06	4.06e-05	CbGpPWpGaD
Pancuronium—CHRM2—Signaling Pathways—CTNNB1—prostate cancer	4.55e-06	4.02e-05	CbGpPWpGaD
Pancuronium—CHRM3—Signaling Pathways—MMP9—prostate cancer	4.51e-06	3.98e-05	CbGpPWpGaD
Pancuronium—CHRM3—Signaling Pathways—CDKN1A—prostate cancer	4.49e-06	3.97e-05	CbGpPWpGaD
Pancuronium—CHRM3—Signaling Pathways—PTEN—prostate cancer	4.48e-06	3.96e-05	CbGpPWpGaD
Pancuronium—CHRM2—Signaling Pathways—MMP9—prostate cancer	4.46e-06	3.94e-05	CbGpPWpGaD
Pancuronium—CHRM2—Signaling Pathways—CDKN1A—prostate cancer	4.45e-06	3.93e-05	CbGpPWpGaD
Pancuronium—CHRM2—Signaling Pathways—PTEN—prostate cancer	4.44e-06	3.92e-05	CbGpPWpGaD
Pancuronium—SLC22A2—Metabolism—PIK3CA—prostate cancer	4.39e-06	3.88e-05	CbGpPWpGaD
Pancuronium—CHRM3—Signaling by GPCR—AKT1—prostate cancer	4.37e-06	3.86e-05	CbGpPWpGaD
Pancuronium—CHRM2—Signaling by GPCR—AKT1—prostate cancer	4.33e-06	3.83e-05	CbGpPWpGaD
Pancuronium—CHRM3—Signaling Pathways—EP300—prostate cancer	4.27e-06	3.78e-05	CbGpPWpGaD
Pancuronium—CHRM2—Signaling Pathways—EP300—prostate cancer	4.23e-06	3.74e-05	CbGpPWpGaD
Pancuronium—CHRM3—Signaling Pathways—SRC—prostate cancer	4.16e-06	3.67e-05	CbGpPWpGaD
Pancuronium—CHRM2—Signaling Pathways—SRC—prostate cancer	4.12e-06	3.64e-05	CbGpPWpGaD
Pancuronium—SLC22A1—Metabolism—PIK3CA—prostate cancer	4.09e-06	3.62e-05	CbGpPWpGaD
Pancuronium—CHRM3—Signaling Pathways—VEGFA—prostate cancer	4.05e-06	3.58e-05	CbGpPWpGaD
Pancuronium—BCHE—Metabolism—AKT1—prostate cancer	4.02e-06	3.55e-05	CbGpPWpGaD
Pancuronium—CHRM2—Signaling Pathways—VEGFA—prostate cancer	4.01e-06	3.54e-05	CbGpPWpGaD
Pancuronium—CHRM3—Signaling Pathways—STAT3—prostate cancer	4.01e-06	3.54e-05	CbGpPWpGaD
Pancuronium—CHRM2—Signaling Pathways—STAT3—prostate cancer	3.97e-06	3.51e-05	CbGpPWpGaD
Pancuronium—CHRM3—Metabolism—PIK3CA—prostate cancer	3.78e-06	3.34e-05	CbGpPWpGaD
Pancuronium—CHRM3—Signaling Pathways—MYC—prostate cancer	3.72e-06	3.29e-05	CbGpPWpGaD
Pancuronium—CHRM3—Signaling Pathways—TGFB1—prostate cancer	3.71e-06	3.28e-05	CbGpPWpGaD
Pancuronium—CHRM2—Signaling Pathways—MYC—prostate cancer	3.69e-06	3.26e-05	CbGpPWpGaD
Pancuronium—CHRM2—Signaling Pathways—TGFB1—prostate cancer	3.68e-06	3.25e-05	CbGpPWpGaD
Pancuronium—CHRM3—Signaling Pathways—EGFR—prostate cancer	3.64e-06	3.22e-05	CbGpPWpGaD
Pancuronium—CHRM2—Signaling Pathways—EGFR—prostate cancer	3.61e-06	3.19e-05	CbGpPWpGaD
Pancuronium—SLC22A2—Metabolism—AKT1—prostate cancer	3.59e-06	3.17e-05	CbGpPWpGaD
Pancuronium—CHRM3—Signaling Pathways—KRAS—prostate cancer	3.44e-06	3.04e-05	CbGpPWpGaD
Pancuronium—CHRM2—Signaling Pathways—KRAS—prostate cancer	3.41e-06	3.01e-05	CbGpPWpGaD
Pancuronium—SLC22A1—Metabolism—AKT1—prostate cancer	3.34e-06	2.95e-05	CbGpPWpGaD
Pancuronium—CHRM3—Signaling Pathways—PIK3CA—prostate cancer	3.16e-06	2.79e-05	CbGpPWpGaD
Pancuronium—CHRM2—Signaling Pathways—PIK3CA—prostate cancer	3.13e-06	2.77e-05	CbGpPWpGaD
Pancuronium—CHRM3—Metabolism—AKT1—prostate cancer	3.09e-06	2.73e-05	CbGpPWpGaD
Pancuronium—CHRM3—Signaling Pathways—TP53—prostate cancer	3.06e-06	2.7e-05	CbGpPWpGaD
Pancuronium—CHRM2—Signaling Pathways—TP53—prostate cancer	3.03e-06	2.68e-05	CbGpPWpGaD
Pancuronium—CHRM3—Signaling Pathways—IL6—prostate cancer	2.8e-06	2.47e-05	CbGpPWpGaD
Pancuronium—CHRM2—Signaling Pathways—IL6—prostate cancer	2.77e-06	2.45e-05	CbGpPWpGaD
Pancuronium—CHRM3—Signaling Pathways—AKT1—prostate cancer	2.58e-06	2.28e-05	CbGpPWpGaD
Pancuronium—CHRM2—Signaling Pathways—AKT1—prostate cancer	2.56e-06	2.26e-05	CbGpPWpGaD
